

Cecile Le Pechoux

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8586589/publications.pdf>

Version: 2024-02-01

51
papers

1,306
citations

516710

16
h-index

434195

31
g-index

52
all docs

52
docs citations

52
times ranked

1565
citing authors

#	ARTICLE	IF	CITATIONS
1	A controlled study of postoperative radiotherapy for patients with completely resected nonsmall cell lung carcinoma. , 1999, 86, 265-273.		223
2	European Organization for Research and Treatment of Cancer (EORTC) recommendations for planning and delivery of high-dose, high precision radiotherapy for lung cancer. Radiotherapy and Oncology, 2017, 124, 1-10.	0.6	177
3	Postoperative radiotherapy versus no postoperative radiotherapy in patients with completely resected non-small-cell lung cancer and proven mediastinal N2 involvement (Lung ART, IFCT 0503): an open-label, randomised, phase 3 trial. Lancet Oncology, The, 2022, 23, 104-114.	10.7	123
4	Baseline metabolic tumor burden on FDG PET/CT scans predicts outcome in advanced NSCLC patients treated with immune checkpoint inhibitors. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 1147-1157.	6.4	103
5	High-dose re-irradiation following radical radiotherapy for non-small-cell lung cancer. Lancet Oncology, The, 2014, 15, e620-e624.	10.7	76
6	Primary Extremity Soft Tissue Sarcomas: Does Local Control Impact Survival?. Annals of Surgical Oncology, 2017, 24, 194-201.	1.5	64
7	Need for a New Trial to Evaluate Adjuvant Postoperative Radiotherapy in Non-“Small-Cell Lung Cancer Patients With N2 Mediastinal Involvement. Journal of Clinical Oncology, 2007, 25, e10-e11.	1.6	55
8	Stereotactic ablative radiotherapy for early stage non-small cell lung cancer: A critical literature review of predictive factors of relapse. Cancer Treatment Reviews, 2016, 50, 240-246.	7.7	38
9	Durvalumab for stage III non-small-cell lung cancer patients: clinical evidence and real-world experience. Therapeutic Advances in Respiratory Disease, 2019, 13, 175346661988553.	2.6	32
10	Brain Radiation Necrosis: Current Management With a Focus on Non-small Cell Lung Cancer Patients. Frontiers in Oncology, 2018, 8, 336.	2.8	26
11	Postoperative radiotherapy for non-small cell lung cancer. , 2016, 9, CD002142.		25
12	Multidisciplinary Tumor Board Decision Making for Postoperative Radiotherapy in Thymic Epithelial Tumors: Insights from the RYTHMIC Prospective Cohort. Journal of Thoracic Oncology, 2017, 12, 1715-1722.	1.1	25
13	Outcome after PORT in ypN2 or R1/R2 versus no PORT in ypN0 Stage III-N2 NSCLC after Induction Chemotherapy and Resection. Journal of Thoracic Oncology, 2016, 11, 1940-1953.	1.1	23
14	ESTRO ACROP guidelines for target volume definition in the thoracic radiation treatment of small cell lung cancer. Radiotherapy and Oncology, 2020, 152, 89-95.	0.6	23
15	Patterns of Locoregional Relapses in Patients with Contemporarily Staged Stage III-N2 NSCLC Treated with Induction Chemotherapy and Resection: Implications for Postoperative Radiotherapy Target Volumes. Journal of Thoracic Oncology, 2016, 11, 1538-1549.	1.1	22
16	The Current Role of Whole Brain Radiation Therapy in Non-“Small Cell Lung Cancer Patients. Journal of Thoracic Oncology, 2017, 12, 1467-1477.	1.1	18
17	Current management of limited-stage SCLC and CONVERT trial impact: Results of the EORTC Lung Cancer Group survey. Lung Cancer, 2019, 136, 145-147.	2.0	17
18	Prophylactic Cranial Irradiation for Limited-Stage Small-Cell Lung Cancer Patients: Secondary Findings From the Prospective Randomized Phase 3 CONVERT Trial. Journal of Thoracic Oncology, 2019, 14, 294-297.	1.1	17

#	ARTICLE	IF	CITATIONS
19	Prophylactic cranial irradiation (PCI), hippocampal avoidance (HA) whole brain radiotherapy (WBRT) and stereotactic radiosurgery (SRS) in small cell lung cancer (SCLC): Where do we stand?. Lung Cancer, 2021, 162, 96-105.	2.0	17
20	Indications and Parameters Around Postoperative Radiation Therapy for Lung Cancer. Journal of Clinical Oncology, 2022, 40, 556-566.	1.6	17
21	A phase II open-label multicenter study of gefitinib in combination with irradiation followed by chemotherapy in patients with inoperable stage III non-small cell lung cancer. Oncotarget, 2017, 8, 15924-15933.	1.8	16
22	Role of adjuvant radiotherapy in completely resected non-small-cell lung cancer. European Journal of Cancer, Supplement, 2013, 11, 123-130.	2.2	15
23	Thoracic radiotherapy in small cell lung cancer—a narrative review. Translational Lung Cancer Research, 2021, 10, 2059-2070.	2.8	14
24	Once daily versus twice-daily radiotherapy in the management of limited disease small cell lung cancer — Decision criteria in routine practise. Radiotherapy and Oncology, 2020, 150, 26-29.	0.6	13
25	Phase II study of concomitant radiotherapy with atezolizumab in oligometastatic soft tissue sarcomas: STEREO-SARC trial protocol. BMJ Open, 2020, 10, e038391.	1.9	12
26	Prognostic value of tumor mutations in radically treated locally advanced non-small cell lung cancer patients. Oncotarget, 2017, 8, 25189-25199.	1.8	12
27	Time interval between surgery and start of adjuvant radiotherapy in patients with soft tissue sarcoma: A retrospective analysis of 1131 cases from the French Sarcoma Group. Radiotherapy and Oncology, 2016, 120, 156-162.	0.6	8
28	Evolving target volume concepts in locally advanced non-small cell lung cancer. Translational Lung Cancer Research, 2021, 10, 1999-2010.	2.8	8
29	Prophylactic Cranial Irradiation or No Prophylactic Cranial Irradiation after Adjuvant Chemotherapy in Resected Small Cell Lung Cancer?. Journal of Thoracic Oncology, 2017, 12, 173-175.	1.1	7
30	Is dose de-escalation possible in sarcoma patients treated with enlarged limb sparing resection?. Radiotherapy and Oncology, 2018, 126, 493-498.	0.6	7
31	Radiosurgery in Patients With Small Cell Lung Cancer With Brain Metastases. JAMA Oncology, 2020, 6, 1037.	7.1	7
32	Strategies for care of patients with gastrointestinal stromal tumor or soft tissue sarcoma during COVID-19 pandemic: A guide for surgical oncologists. Journal of Surgical Oncology, 2021, 123, 12-23.	1.7	7
33	Tumour motion management in lung cancer: a narrative review. Translational Lung Cancer Research, 2021, 10, 2011-2017.	2.8	7
34	Individual patient data meta-analysis of prophylactic cranial irradiation in locally advanced non-small cell lung cancer. Radiotherapy and Oncology, 2021, 158, 40-47.	0.6	7
35	Can radiation-recall predict long lasting response to immune checkpoint inhibitors?. Radiotherapy and Oncology, 2021, 154, 125-127.	0.6	7
36	18F-FDG PET and DCE kinetic modeling and their correlations in primary NSCLC: first voxel-wise correlative analysis of human simultaneous [18F]FDG PET-MRI data. EJNMMI Research, 2020, 10, 88.	2.5	7

#	ARTICLE	IF	CITATIONS
37	Treatment related factors associated with the risk of breast radio-induced-sarcoma. Radiotherapy and Oncology, 2022, 171, 14-21.	0.6	6
38	In Regard to Koshy et al. International Journal of Radiation Oncology Biology Physics, 2015, 92, 945-946.	0.8	5
39	Surgical management of soft tissue tumors of the abdominal wall: A retrospective study in a high-volume sarcoma center. Journal of Surgical Oncology, 2021, 124, 679-686.	1.7	4
40	Challenges in the treatment of early non-small cell lung cancer: what is the standard, what are the challenges and what is the future for radiotherapy?. Translational Lung Cancer Research, 2014, 3, 195-204.	2.8	4
41	Stereotactic ablative body radiation therapy or surgery for operable early non-small cell lung cancer patients: bound hand and foot to evidence. Journal of Thoracic Disease, 2017, 9, 482-484.	1.4	2
42	Focus on Recommendations for the Management of Non-small Cell Lung Cancer. CardioVascular and Interventional Radiology, 2019, 42, 1230-1239.	2.0	2
43	Hippocampal Avoidance Whole-Brain Radiotherapy (WBRT) Versus WBRT in Patients With Brain Metastases: Were Hippocampi the Only Difference?. Journal of Clinical Oncology, 2020, 38, 3453-3454.	1.6	2
44	Cost-effectiveness of prophylactic cranial irradiation in stage III non-small cell lung cancer. Radiotherapy and Oncology, 2022, 170, 95-101.	0.6	2
45	Twice-daily chemoradiotherapy in limited-stage small-cell lung cancer. Lancet Oncology, The, 2021, 22, e220.	10.7	1
46	Prospective evaluation of intensity-modulated radiotherapy toxicity in extremity soft tissue sarcomas patients: A role for irradiated healthy soft tissue volume?. Clinical and Translational Radiation Oncology, 2021, 29, 79-84.	1.7	1
47	Stage III NSCLC in Low- and Middle-Income Countries: Where Are We in 2021?. Journal of Thoracic Oncology, 2021, 16, 1605-1606.	1.1	1
48	Inoperable scalp cutaneous angiosarcoma: Complete response after definitive external beam radiation therapy + brachytherapy association. Oral Oncology, 2022, 125, 105715.	1.5	1
49	Check the Reports and Check the Brain. International Journal of Radiation Oncology Biology Physics, 2019, 104, 711-712.	0.8	0
50	Multimodal approach: combining radiation therapy with immunotherapy in solid tumors. Future Oncology, 2020, 16, 1669-1671.	2.4	0
51	Association of different fractionation schedules for prophylactic cranial irradiation with toxicity and brain metastases-free survival in stage III non-small cell lung cancer: A pooled analysis of individual patient data from three randomized trials. Radiotherapy and Oncology, 2021, 164, 163-166.	0.6	0